Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

You have full access to this article via your institution. Figure 1: Reconstitution of hematopoiesis with GFP-expressing peripheral-blood cell progeny in lethally irradiated mice after ...